GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS)

Clinical trials for GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS) explained in plain language.

Never miss a new study

Get alerted when new GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS) trials appear

Sign up with your email to follow new studies for GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Scientists test gentler schedule for powerful cancer drug

Disease control Recruiting now

This study is for people with a specific type of slow-growing digestive tract cancer. It is testing if giving the same radioactive drug treatment less often (every 16 weeks instead of every 8 weeks) can cause fewer serious side effects, especially blood-related problems, while st…

Matched conditions: GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS)

Phase: PHASE3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control

Last updated Mar 11, 2026 14:53 UTC

GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS)

Get alerted when new GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS) trials appear

Scientists test gentler schedule for powerful cancer drug